Tetanus toxoid immunization to reduce mortality from neonatal tetanus by Blencowe, Hannah et al.
Tetanus toxoid immunization to reduce
mortality from neonatal tetanus
Hannah Blencowe,
1 Joy Lawn,
2,3 Jos Vandelaer,
4 Martha Roper
5 and Simon Cousens
1
1London School of Hygiene and Tropical Medicine, London, UK,
2Saving Newborn Lives/Save the Children-USA, Cape Town,
South Africa,
3Health Systems Strengthening Unit, Medical Research Council, Cape Town, South Africa,
4UNICEF, Health Section,
New York, USA and
5WHO, Department of Immunisation, Vaccines and Biologicals, Geneva, Switzerland.
Corresponding author. Simon Cousens, London School of Hygiene and Tropical Medicine, Keppel Street, London, UK.
E-mail: simon.cousens@lshtm.ac.uk
Background Neonatal tetanus remains an important and preventable cause of
neonatal mortality globally. Large reductions in neonatal tetanus
deaths have been reported following major increases in the cover-
age of tetanus toxoid immunization, yet the level of evidence for
the mortality effect of tetanus toxoid immunization is surprisingly
weak with only two trials considered in a Cochrane review.
Objective To review the evidence for and estimate the effect on neonatal tet-
anus mortality of immunization with tetanus toxoid of pregnant
women, or women of childbearing age.
Methods We conducted a systematic review of multiple databases.
Standardized abstraction forms were used. Individual study quality
and the overall quality of evidence were assessed using an adapta-
tion of the GRADE approach. Meta-analyses were performed.
Results Only one randomised controlled trial (RCT) and one well-controlled
cohort study were identified, which met inclusion criteria for
meta-analysis. Immunization of pregnant women or women of
childbearing age with at least two doses of tetanus toxoid is esti-
mated to reduce mortality from neonatal tetanus by 94% [95%
confidence interval (CI) 80–98%]. Additionally, another RCT with
a case definition based on day of death, 3 case–control studies and
1 before-and-after study gave consistent results. Based on the con-
sistency of the mortality data, the very large effect size and that the
data are all from low/middle-income countries, the overall quality
of the evidence was judged to be moderate.
Conclusion This review uses a standard approach to provide a transparent
estimate of the high impact of tetanus toxoid immunization on
neonatal tetanus.
Keywords neonatal mortality, newborn care, neonatal tetanus, tetanus toxoid,
immunization
Background
Neonatal tetanus was estimated to be responsible for
over half a million neonatal deaths globally in early
1980s.
1 Estimates suggest that these deaths have been
reduced, but that still some 130000 babies died
around the year 2004 from this very preventable dis-
ease.
2 Despite this impressive progress, two global
elimination target dates have been missed, most
recently in 2005, to a rate of ‘less than 1 case per
1000 livebirths in every district of every country’.
Most of the remaining deaths from neonatal tetanus
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i102occur in a limited number of large countries with low
coverage of facility births and tetanus toxoid immu-
nization, such as India and Nigeria.
Neonatal tetanus is an acute disease presenting ini-
tially with loss of ability to suck, followed by general-
ized rigidity and painful muscle spasms as the disease
progresses. The disease is caused by tetanus toxin
produced by Clostridium tetani. The commonest port
of entry for the tetanus spores is the unhealed umbil-
ical cord. Most (90%) cases of neonatal tetanus
develop symptoms during the first 3–14 days of life
with the majority presenting at 6–8 days.
1 Mortality
tends to be very high: in the absence of medical treat-
ment, case fatality approaches 100%; with hospital
care 10–60% of NT cases die, depending on the avail-
ability of intensive care facilities.
1 Clearly, prevention
measures for tetanus are more effective than case
management even if full intensive care were available,
and certainly much more cost-effective.
3
Even before tetanus vaccine was available, neonatal
tetanus became increasingly rare in most of Europe
and North America through hygienic childbirth prac-
tices and cord care.
4,5 The advent of the vaccine
resulted in further reduction in high-income coun-
tries, and also opened opportunities for progress in
low-income settings. The vaccine is an inactivated
toxin (toxoid) that was first produced in 1924.
6 It
became commercially available in 1938 and was suc-
cessfully used extensively during the Second World
War. In the late 1940s, it was combined with diphtheria
and pertussis vaccines to produce the DTP triple vaccine
used in many childhood immunization programmes.
A trial in Papua New Guinea published in 1961 was
the first demonstration that use of two or more doses
of tetanus toxoid during pregnancy could prevent
neonatal tetanus.
7 In the mid-1970s, tetanus toxoid
vaccination of pregnant women was included in the
WHO’s Expanded Program on Immunization.
4
Concentrations of tetanus anti-toxin exceeding
0.1–0.15IU/ml, measured by standard (indirect)
enzyme linked immunosorbent assay, are considered
protective. These are achieved 24 weeks after the
second dose of tetanus toxoid in 90% of adults.
Although immunity wanes over time, more than
three-quarters of women will maintain ‘protective
levels’ for 3 years. A third dose given 6–12 months
after the first two doses increases both the level of
neutralizing IgG antibody and duration of immunity
for at least an additional 5 years. Additional doses
given at least 1 year apart further prolong duration
of protection; after the fifth dose, protective antibody
levels last for at least 20 years.
8
Tetanus antitoxin is actively transported by the pla-
centa from an immunized mother to her fetus, pro-
viding passive protection against tetanus during the
neonatal period and the following month or two of
life. Maternal and neonatal tetanus antibody concen-
trations at the time of delivery are usually similar.
8
However, placental antibody transfer may be reduced
in the presence of maternal malaria and HIV infec-
tions.
9–11
While tetanus immunization is now a standard
practice, the evidence base to support the mortality
effect estimate for use in the LiST tool is limited,
mainly because the vaccine was accepted for practice
before the era of randomized controlled trials. The
Cochrane review (‘Vaccines for women to prevent
neonatal tetanus’) includes two trials, one from
Columbia in 1966 and the second from Bangladesh
in 1980.
12
Objective
The objective of this article is to provide an estimate
of the effect on neonatal tetanus mortality of immu-
nization of pregnant women, or women of childbear-
ing age, with two or more doses of tetanus toxoid for
use in the LiST tool.
Methods
We systematically reviewed the published literature to
identify studies of tetanus toxoid immunization of
women for the prevention of neonatal tetanus mor-
tality for use in the LiST model. In the model,
increases in coverage of an intervention results in a
reduction of one or more cause-specific deaths. The
review and the GRADE process used were designed to
develop estimates of the effect in reducing neonatal
mortality. For more details on the review methods,
the adapted grade approach or the LiST model see
other articles in this supplement.
We searched PubMed, EMBASE, Cochrane Libraries
and all World Health Organization Regional Databases
and included publications in any language.
13
Combinations of the following search terms were
used: ‘neonatal tetanus, tetanus toxoid, neonatal mor-
tality and women’.
Inclusion/exclusion criteria
We applied the PICO format (Patient, Intervention,
Comparison and Outcome) to define the studies to
be included as follows. The ‘population’ of interest
were neonates, and the ‘intervention’ was at least
two tetanus toxoid vaccine doses, given at least
4 weeks apart, with the last dose given during the
current pregnancy. The comparison group were
those neonates born after pregnancies without teta-
nus toxoid immunization. The outcome of interest
was mortality from neonatal tetanus (Box 1). We con-
sidered both randomized trials and observational stu-
dies meeting these criteria (Figure 1). We excluded
studies not fulfilling the inclusion criteria, studies
reporting serological outcomes only and any duplicate
reports of trials or studies (Figure 1).
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All studies meeting the inclusion/exclusion criteria
were abstracted onto a standardized abstraction
form for each outcome of interest.
13 Each study was
assessed and graded according to the CHERG adapta-
tion of the GRADE technique.
14 The evidence was
summarized by outcomes including qualitative assess-
ment of study quality. CHERG Rules for Evidence
Review were applied to the collective evidence to pro-
vide an estimate for reduction in neonatal tetanus
mortality. We conducted a meta-analysis using
STATA version 10.0 statistical software
15 and reported
the Mantel–Haenszel pooled relative risk and corre-
sponding 95% confidence interval (CI).
Results
The literature search identified 1358 papers (Figure 2).
After initial screening of the title or abstract,
we reviewed the full text of 54 papers. Thirty-two of
these papers were not abstracted as they contained
no mortality data. Data were abstracted from 22
papers. Expert review of the studies abstracted iden-
tified two further relevant studies. The following
BOX 1
Cause-specific mortality effect and quality grade
of the estimate for the effect of tetanus toxoid
immunization.
  Cause-specific mortality to act on:
Neonatal tetanus.
  Cause-specific effect and range:
94% (80–98%).
  Quality of input evidence:
Moderate (one RCT and one cohort study in
low/middle-income countries; mortality data
consistent; and very large effect, hence quality
upgraded from low to moderate).
Supported by low-quality evidence from one
RCT, three case–control studies and one before
and after study.
  Proximity of the data to cause-specific
mortality effect:
High (cause-specific mortality).
  Limitations of the evidence:
Only two studies are included in the effect size
estimate, one of which was an RCT.
Case 
Control
5
1
Excluded studies
Excluded as not 
cause specific mortality Observational/ survey
7
Figure 1 Synthesis of study identification in the review of the effect of tetanus toxoid immunization on mortality from
neonatal tetanus.
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studies
7, 16–24 and 5 case–control studies,
25–29 which
made no attempt to control for confounding and
1 study with multiple concurrent interventions
where it was impossible to separate the effect of tet-
anus toxoid from the other interventions
30 and
1 study which had used sub-potent vaccine
31
(Supplementary Table 1). Where studies reported
effects of one dose and of two doses, we restricted
analysis to the effect of two doses.
Seven studies were included in the final database
(Supplementary Table 1). We identified two studies
of high/moderate-quality reporting neonatal tetanus
mortality.
32–33 One was a high-quality randomised
controlled trial (RCT) and the second a cohort study
which was well designed with adjustment for con-
founding in its analysis. There was no strong evidence
of heterogeneity between the two studies (P¼0.16).
Hence, the data were combined in one meta-analysis
giving an estimate of effect of relative risk (RR)
¼0.06 (95% CI 0.02–0.2) (Figure 2).
A third study, identified in the Cochrane review was
a RCT assessing all-cause neonatal mortality from day
4–14 as a proxy for neonatal tetanus mortality. The
trial was originally designed to test a cholera vaccine
and tetanus toxoid was given to participants in the
control group. The estimated relative risk of neonatal
mortality (4–14 days) was 0.33 (95% CI 0.21–0.50).
34
This figure is likely to substantially underestimate the
effect on neonatal tetanus mortality, as a number of
the deaths during this period would have been due to
other causes (e.g. sepsis and complications of prema-
turity) not susceptible to prevention through tetanus
toxoid immunization.
Four papers reporting the effect of tetanus toxoid
immunization on the occurrence of neonatal tetanus
were also abstracted (Supplementary Table 1). Three
case–control studies
35–37 whose design controlled for
confounding reported a protective effect of two doses
of tetanus toxoid in the current pregnancy [odds ratio
(OR)¼0.05 (0.005–0.4); OR¼0.1 (0.03–0.4); OR¼0.2
(0.03–0.7]. A study of hospital neonatal tetanus
admission rates pre- and post-mass immunization
campaign reported a reduction in neonatal tetanus
admissions, RR¼0.35 (95% CI 0.29–0.42).
38
The CHERG Rules for Evidence Review were
applied.
13 The effect seen was large and broadly con-
sistent across different types of study. There were
71 neonatal tetanus deaths in the two highest quality
studies with an overall evidence grade of moderate,
hence more than the minimum of 50 events were
required by the CHERG rules (Box 1). The evidence
grade allocated is moderate, upgraded from low
because although the input data are limited, the
effect size is very large and is consistent across the
various data identified.
Discussion
Mortality from neonatal tetanus remains an impor-
tant, yet preventable, cause of neonatal mortality.
Heterogeneity chi-squared =   1.94 (d.f. = 1) p = 0.164 
I-squared (variation in RR attributable to heterogeneity) =  48.5% 
Test of RR=1 : z=   4.73 p<0.001 
Overall  (I-squared = 48.5%, p = 0.164)
gupta 1998
newell 1966
ID
0.06 (0.02, 0.20)
0.12 (0.04, 0.41)
0.02 (0.00, 0.31)
RR (95% CI)
100.00
40.97
59.03
Weight
1 .1 10
Figure 2 Meta-analysis of the effect of tetanus toxoid on neonatal tetanus mortality
TETANUS TOXOID IMMUNIZATION i105Our systematic review identified three studies of
moderate-quality providing supporting evidence of a
large effect of tetanus toxoid immunization on neo-
natal tetanus mortality, when at least two doses are
given at least 4 weeks apart with the last dose given
during the current pregnancy. Applying CHERG Rules
for Evidence Reviews for LiST, our new meta-analysis
includes two trials with cause-specific mortality and
gives an estimate that two or more properly timed
doses of tetanus toxoid immunization given to preg-
nant women or women of childbearing age will
reduce neonatal tetanus mortality by 94% (95% CI
80–98%).
The main limitation of this review and the resulting
effect estimate is the dearth of high-quality trials. Our
estimate is based on two studies including 2146
women and 71 neonatal tetanus deaths. However,
there is consistency with one other moderate-quality
study with deaths by day 14 and with the 19 other,
lower quality observational studies reviewed. There is
moderate-quality evidence to suggest that this strat-
egy can reduce the risk of neonatal tetanus mortality
by 490%.
Tetanus toxoid immunization of pregnant women
is currently recommended by WHO and is included
in the immunization policy of most Member
States.
39 Widespread programmatic use of tetanus
toxoid has removed the equipoise required to carry
out randomized studies and has also con-
vincingly reduced the global burden of deaths from
neonatal tetanus by  90% in the past 25 years
(Figure 3).
5 There are strong grounds for recommend-
ing immunization of pregnant women or women of
childbearing age with tetanus toxoid to prevent neo-
natal tetanus. Immunization, in combination with
clean, hygienic delivery practices remains of central
importance if global elimination goals are to be met
finally.
Progress towards elimination of neonatal tetanus
that is being made with a number of low-income
countries have been validated as reaching
Elimination Status. Ninety countries had not elimi-
nated maternal and neonatal tetanus in 1990.
40 That
figure has now been reduced to 44 countries.
41
However, there remains an unfinished agenda espe-
cially in a few large countries with low coverage of
facility births and low tetanus toxoid immunization.
In addition, as tetanus spores are ubiquitous and
eradication is not an option, ongoing attention to
maintaining high levels of tetanus toxoid immuniza-
tion is required, as well as strengthening and integrat-
ing national surveillance systems.
Conclusion
This review provides clear evidence of the high impact
of two doses of tetanus toxoid immunization given at
least 4 weeks apart on neonatal tetanus. Given the low
additional cost of the immunization at around 60 cents
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i106 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYper dose, including full operational costs, and the fea-
sibility of reaching high coverage even in weak health
care systems, the recurrent failure to reach global elim-
ination goals is hard to justify. With recent investments
in the campaign for Maternal and Neonatal Tetanus
Elimination, there appears to be more substantial
progress (Figure 4). The next few years will be critical
to finally meeting Elimination goals.
Source: WHO/UNICEF estimates and WHO/IVB database, 2008
193 WHO Member States. Data as of October 2008
MNT eliminated in < 50% of districts (6 countries)
MNT eliminated in 50% - 99% of districts (38 countries)
MNT eliminated prior to 2000 (135 countries)
MNT eliminated since 2000 (14 countries & 15 States in India)
The boundaries and names shown and the designations used on this map 
do not imply the expression of any opinion whatsoever on the part of the 
World Health Organization concerning the legal status of any country, 
territory, city or area or of its authorities, or concerning the delimitation 
of its frontiers or boundaries.  Dotted lines on maps represent 
approximate border lines for which there may not yet be full agreement. 
© WHO 2009. All rights reserved
Source: WHO/UNICEF estimates and WHO/IVB database, April 2009
193 WHO Member States. Data as of April 2009
Figure 4 Global and national progress towards maternal and neonatal tetanus elimination. Source: Map courtesy
of WHO – reproduced with permission, http://www.who.int/immunization_monitoring/diseases/MNTE_initiative/en/
index4.html
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Figure 3 Global and national progress towards maternal and neonatal tetanus elimination. Source: Updated from Roper
et al.
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KEY MESSAGES
  A very large effect of tetanus toxoid immunization on reducing neonatal mortality from neonatal
tetanus is observed based on a moderate level of evidence.
  Tetanus toxoid immunization coverage is increasing with progress being made towards maternal and
neonatal tetanus elimination.
  High levels of immunization and strengthening and integrating surveillance systems are required to
maintain progress and meet elimination targets.
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